Overview

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The FIRE-3 trial is a multicenter randomized phase III trial investigating 5-FU, folinic acid and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment of metastatic colorectal cancer. Planned accrual is 284 evaluable patients per treatment arm. The primary study endpoint is objective response rate. Secondary endpoints are median progression free survival, median overall survival, safety, and secondary resection rate.

Phase:

Phase 3

Details

Lead Sponsor:

PD Dr. med. Volker Heinemann

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Bevacizumab
Cetuximab
Folic Acid
Irinotecan
Leucovorin
Levoleucovorin